Impact of Individualized Neoantigen Therapies on Health, Productivity and Health System Capacity Outcomes in Resectable Melanoma in England
Author(s)
Chien-Jhih Tsai, MSc1, Izzy Thornton, MSc1, Catarina Neves, MSc2, Hannah Burton, MSc3, Ying Xiao, M.H.S.A4, Christopher Black, MPH, PhD4;
1Lumanity, London, United Kingdom, 2Lumanity, Utrecht, Netherlands, 3Merck Sharp & Dohme (UK) Ltd, London, United Kingdom, 4Merck & Co., Inc., Rahway, NJ, USA
1Lumanity, London, United Kingdom, 2Lumanity, Utrecht, Netherlands, 3Merck Sharp & Dohme (UK) Ltd, London, United Kingdom, 4Merck & Co., Inc., Rahway, NJ, USA
Presentation Documents
OBJECTIVES: The NHS Long Term Plan seeks to improve cancer survival, partly by increasing early diagnoses. Better outcomes from early diagnosis hinge on rapid, effective treatment. As individualized neoantigen therapies (INTs) are being investigated for various cancers with promising early results, understanding their potential long-term impact is crucial. We estimated potential health, productivity, and health system capacity outcomes of introducing INTs for patients with resectable melanoma in England.
METHODS: A four-state Markov model with weekly cohort entry included patients with resectable Stage IIIB-IV melanoma and compared outcomes over 10 years for two scenarios: (a) INTs may be used as adjuvant treatment, and (b) only traditional adjuvant treatments are available. Inputs included clinical trial data, national epidemiology statistics, and market share estimates. A sensitivity analysis exploring a projected future increase in the melanoma incidence rate was also conducted.
RESULTS: Over 10 years, 9,163 (sensitivity analysis 9,987; 68%) of the 13,416 (14,623) patients eligible for adjuvant therapy for melanoma were estimated to initiate treatment with INTs (instead of traditional treatments). This is anticipated to increase eligible population life years (LYs) without recurrence by 3,092 (3,370; 8%) and quality-adjusted life years (QALYs) by 1,341 (1,461; 3%), while avoiding 1,207 (1,315; 19%) recurrences, 1,010 (1,101; 17%) patients from requiring metastatic treatment and 457 (498; 15%) deaths. It is also anticipated to result in 12,292 (13,399; 18%) fewer intravenous metastatic treatment administrations needed, and 2,696 (2,939; 15%) productive years gained for both patients and caregivers.
CONCLUSIONS: INTs currently in development have the potential to bring substantial health outcome and productivity benefits. By increasing recurrence-free and overall survival, INTs can help lower absenteeism and presenteeism, resulting in work productivity gains. Introducing INTs as a potential adjuvant treatment has the potential to reduce the number of metastatic treatment administrations required, alleviating the associated NHS burden.
METHODS: A four-state Markov model with weekly cohort entry included patients with resectable Stage IIIB-IV melanoma and compared outcomes over 10 years for two scenarios: (a) INTs may be used as adjuvant treatment, and (b) only traditional adjuvant treatments are available. Inputs included clinical trial data, national epidemiology statistics, and market share estimates. A sensitivity analysis exploring a projected future increase in the melanoma incidence rate was also conducted.
RESULTS: Over 10 years, 9,163 (sensitivity analysis 9,987; 68%) of the 13,416 (14,623) patients eligible for adjuvant therapy for melanoma were estimated to initiate treatment with INTs (instead of traditional treatments). This is anticipated to increase eligible population life years (LYs) without recurrence by 3,092 (3,370; 8%) and quality-adjusted life years (QALYs) by 1,341 (1,461; 3%), while avoiding 1,207 (1,315; 19%) recurrences, 1,010 (1,101; 17%) patients from requiring metastatic treatment and 457 (498; 15%) deaths. It is also anticipated to result in 12,292 (13,399; 18%) fewer intravenous metastatic treatment administrations needed, and 2,696 (2,939; 15%) productive years gained for both patients and caregivers.
CONCLUSIONS: INTs currently in development have the potential to bring substantial health outcome and productivity benefits. By increasing recurrence-free and overall survival, INTs can help lower absenteeism and presenteeism, resulting in work productivity gains. Introducing INTs as a potential adjuvant treatment has the potential to reduce the number of metastatic treatment administrations required, alleviating the associated NHS burden.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO94
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
SDC: Oncology, STA: Personalized & Precision Medicine